This patent is one of the foundational intellectual property protections covering tirzepatide, the active ingredient in Eli Lilly branded products Mounjaro and Zepbound
While Ozempic is not FDA-approved for weight management, it is sometimes used off-label for this purpose due to its ability to reduce appetite and promote weight loss
Part of that reflects intensifying competition from Eli Lilly, which now commands 58% of total U.S
Clinical studies show that patients typically lose 10-20% of their body weight over several months with GLP-1 therapy
its designed to extend it. The need is especially urgent as more patients consider what comes after GLP-1 treatment
For diabetes-indicated GLP-1 medications including Ozempic, Trulicity, Victoza, Byetta, Bydureon, and Rybelsus, headache is typically classified as common (affecting between 1 in 10 and 1 in 100 people)